FYI

I am copying and pasting the below information (in itlalics) from the natural living/attachment parenting board of the charlottemommies.com website. Before people run out and jump on the swine flu vaccine bandwagon, I hope they at *least* educate themselves to the ingredients and recommendations. I find it interesting that the mainstream media keeps saying how pregnant women will be/should be vaccinated first. Yet, the package inserts FROM THE MANUFACTURER flat out says "It is also not known whether these vaccines can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity." Scary. I hope all pregnant women are actually made aware of this info, and not just bullied or scared into getting an unproven and untested vaccine. In that, I mean unproven and untested for pregnant women. If they just started trials a few months ago, then that means there is NO WAY a woman got it in the first trimester, and has had a term baby yet. So YES, that means it's untested.

The FDA has approved the Swine Flu Vax from the following manufacturers. Remember that at least two doses will likely be given. The following package inserts are available. There is not a Swine Flu shot recommended for under 6 months of age (but, during a pandemic, not sure if this still applies). Flu Mist is not recommended under the age of two. Read each package insert carefully. It seems like the multidose have mercury:


http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181950.htm


Injectable Vaccines
Influenza A (H1N1) 2009 Monovalent Vaccine (CSL Limited)Mercury & No Mercury

Influenza A (H1N1) 2009 Monovalent Vaccine (Novartis Vaccines and Diagnostics Limited) Mercury

Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur, Inc.) Mercury and no Mercury


Intranasal Vaccine (THIS IS A LIVE VIRUS)-No Mercury
(Influenza A (H1N1) 2009 Monovalent Vaccine (MedImmune LLC)

Ingredients:Each pre-filled refrigerated Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal sprayer contains a single 0.2 mL dose. Each 0.2 mL dose contains 106.5-7.5 FFU of the live attenuated influenza virus reassortant of the pandemic (H1N1) 2009 virus: A/California/7/2009 (H1N1)v. Each 0.2 mL dose also contains 0.188 mg/dose monosodium glutamate, 2.00 mg/dose hydrolyzed porcine gelatin, 2.42 mg/dose arginine, 13.68 mg/dose sucrose, 2.26 mg/dose dibasic potassium phosphate, 0.96 mg/dose monobasic potassium phosphate, and <0.015>Influenza A (H1N1) 2009 Monovalent Vaccine (CSL Limited):

􀂃Indicated for active immunization of persons 6 months of age and older
supplied in four presentations:
Prefilled syringe, 0.25 mL, no preservative; distinguished by a pink syringe plunger rod (3)
Prefilled syringe, 0.5 mL, no preservative (3)
Single-dose vial, 0.5 mL, no preservative (3)
Multi-dose vial, 5 mL, contains thimerosal, a mercury derivative, added as a preservative. Each 0.5 mL dose contains 25 mcg mercury. (3, 11 )
􀂃Vaccine have not been established in pregnant women or nursing mothers or children <6>Description
The virus-containing allantoic fluid is harvested and inactivated with formaldehyde.Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether (Triton® X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution.
Influenza A (H1N1) 2009 Monovalent Vaccine is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009 (H1N1) v-like virus per 0.5 mL dose. Gelatin 0.05% is added as a stabilizer. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 100 mcg), polyethylene glycol p-isooctylphenyl ether (not more than 0.02%), and sucrose (not more than 2.0%).
There is no thimerosal used in the manufacturing process of the single-dose presentations of Influenza A (H1N1) 2009 Monovalent Vaccine. The multi-dose presentation of Influenza A (H1N1) 2009 Monovalent Vaccine contains thimerosal, a mercury derivative, added as a preservative. Each 0.5 mL dose of the multidose presentation contains 25 mcg mercury.
--Neither Fluzone vaccine nor Influenza A (H1N1) 2009 Monovalent Vaccine have been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility